Cargando…

Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans

Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zagaliotis, Panagiotis, Michalik-Provasek, Jordyn, Gill, Jason J., Walsh, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pathogens and Immunity 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596135/
https://www.ncbi.nlm.nih.gov/pubmed/36320594
http://dx.doi.org/10.20411/pai.v7i2.516
_version_ 1784815801320079360
author Zagaliotis, Panagiotis
Michalik-Provasek, Jordyn
Gill, Jason J.
Walsh, Thomas J.
author_facet Zagaliotis, Panagiotis
Michalik-Provasek, Jordyn
Gill, Jason J.
Walsh, Thomas J.
author_sort Zagaliotis, Panagiotis
collection PubMed
description Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Salmonella typhimurium. The extended use of antibiotics has led to the emergence of multidrug resistance in these bacteria. Drug-inactivating enzymes produced by these bacteria, as well as other resistance mechanisms, render drugs ineffective and make treatment of such infections more difficult and complicated. This makes the development of novel antimicrobial agents an urgent necessity. Bacteriophages, which are bacteria-killing viruses first discovered in 1915, have been used as therapeutic antimicrobials in the past, but their use was abandoned due to the widespread availability of antibiotics in the 20th century. The emergence, however, of drug-resistant pathogens has re-affirmed the need for bacteriophages as therapeutic strategies. This review describes the use of bacteriophages as novel agents to combat this rapidly emerging public health crisis by comprehensively enumerating and discussing the innovative use of bacteriophages in both animal models and in patients infected by Gram-negative bacteria.
format Online
Article
Text
id pubmed-9596135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Pathogens and Immunity
record_format MEDLINE/PubMed
spelling pubmed-95961352022-10-31 Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans Zagaliotis, Panagiotis Michalik-Provasek, Jordyn Gill, Jason J. Walsh, Thomas J. Pathog Immun Review Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Salmonella typhimurium. The extended use of antibiotics has led to the emergence of multidrug resistance in these bacteria. Drug-inactivating enzymes produced by these bacteria, as well as other resistance mechanisms, render drugs ineffective and make treatment of such infections more difficult and complicated. This makes the development of novel antimicrobial agents an urgent necessity. Bacteriophages, which are bacteria-killing viruses first discovered in 1915, have been used as therapeutic antimicrobials in the past, but their use was abandoned due to the widespread availability of antibiotics in the 20th century. The emergence, however, of drug-resistant pathogens has re-affirmed the need for bacteriophages as therapeutic strategies. This review describes the use of bacteriophages as novel agents to combat this rapidly emerging public health crisis by comprehensively enumerating and discussing the innovative use of bacteriophages in both animal models and in patients infected by Gram-negative bacteria. Pathogens and Immunity 2022-10-17 /pmc/articles/PMC9596135/ /pubmed/36320594 http://dx.doi.org/10.20411/pai.v7i2.516 Text en Copyright © 2022 Pathogens and Immunity https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Zagaliotis, Panagiotis
Michalik-Provasek, Jordyn
Gill, Jason J.
Walsh, Thomas J.
Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
title Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
title_full Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
title_fullStr Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
title_full_unstemmed Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
title_short Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
title_sort therapeutic bacteriophages for gram-negative bacterial infections in animals and humans
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596135/
https://www.ncbi.nlm.nih.gov/pubmed/36320594
http://dx.doi.org/10.20411/pai.v7i2.516
work_keys_str_mv AT zagaliotispanagiotis therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans
AT michalikprovasekjordyn therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans
AT gilljasonj therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans
AT walshthomasj therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans